Resources &

Events

Paradigm conducts research and development days, investor roadshows, investor days, virtual conferences and webinars and clinical updates. To stay up to date with everything happening at Paradigm, join our mailing list.  

Next R&D Event
EventXVII International Conference on Lysosomal Diseases
LocationSydney, Australia
DateFeb 20-21, 2023

Last updated 27/09/22 11:00am

Next Investor Event
EventParadigm AGM
LocationMelbourne, Victoria
DateNov 29, 2022

Last updated 28/10/22 3:47pm

Upcoming Events

Shifts in Thinking

Read how the Paradigm team is approaching innovation from completely different approach below. For all published articles please click here

WorldSymposium Poster
Safety and tolerability of PPS in MPS VI
Author: Roberto Giugliani et al.
February 22, 2022
ICIEM Poster
Safety and tolerability of PPS in MPS I
Author: Drago Bratkovic et al.
November 22, 2021
Performance Report
J.P Morgan Healthcare Conference 2022
Author: Simon White
January 22, 2022
Development Plan
Potential of injectable PPS for knee OA
Author: Mukesh Ahuja MBBS, MS
May 22, 2022
Previous
Next

Peer-Reviewed Publications

MPS VI: defining and measuring functional impacts in pediatric patients
Source: Leiro B, et al
December 2, 2021
Double-blind placebo-controlled phase 2 study to evaluate the safety & tolerability of PPS in subjects with MPS VI
Source: Giugliani, R. et. al.
February 10, 2022
An open-label single-centre pilot study to evaluate the safety and tolerability of PPS in subjects with MPS I
Source: Bratkovic, D. et al
November 23, 2021
Summary of peer reviewed publications supporting PPS mechanism of action for the treatment of osteoarthritis
Source: Paradigm Biopharma
August 5, 2021
Human osteocyte expression of Nerve Growth Factor: The effect of PPS & implications for pain associated with knee osteoarthritis
Source: Stapledon C. et al
September 26, 2019
Improved clinical outcome measures of knee pain & function with concurrent resolution of subchondral BME lesion and joint effusion in an osteoarthritic patient following PPS treatment: a case report
Source: Sampson, M. et al
September 12, 2017
Broad Th2 neutralization and anti-inflammatory action of PPS in experimental allergic rhinitis
Source: Sanden, C. et al
May 12, 2017
PPS: a novel glycosaminoglycan-like molecule for effective treatment of alphavirus-induced cartilage destruction & inflammatory Disease
Source: Herrero, L.J. et al
May 27, 2015
PPS decreases myocardial expression of the extracellular matrix enzyme ADAMTS4 & improves cardiac function in vivo in rats subjected to pressure overload by aortic banding
Source: Vistnes, M. et al
March 3, 2014

In the Media

Small Caps
Paradigm raises the stakes in osteoarthritis pain reduction
Focus: Osteoarthritis
August 15, 2018
WFAA USA
WFAA USA reports on Paradigms’ Expanded Access
Focus: Expanded access
August 20, 2020
AFR
Footballers Chris Judd, Leo Barry pile into Paradigm Raising
Focus: Capital Raise
December 13, 2019
NINE NEWS
Report on Andrew Walker and Paradigms’ EAP in the USA
Focus: Osteoarthritis
August 26, 2020
Previous
Next

Media Archive